Literature DB >> 7594508

Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells.

A Khoruts1, S D Miller, M K Jenkins.   

Abstract

We have identified a method of polarizing polyclonal populations of activated T helper cells toward either the Th1 or Th2 phenotype using different short-term in vitro culture conditions. Since the Ag used was an encephalitogenic peptide for SJL/J mice, the pathogenic potential of these cell populations was tested in an adoptive transfer model of experimental autoimmune encephalomyelitis (EAE). Th1 cells reproducibly caused severe EAE, whereas highly polarized Th2 cells did not. Furthermore, highly polarized Th2 cells did not suppress EAE caused by Th1 cells. The anti-inflammatory cytokines made by Th2 cells may simply fail to inhibit tissue destruction mediated by differentiated Th1 cells at the effector phase of the disease. It is also possible that highly polarized Th2 cells may be inefficient at crossing the blood-brain barrier, which may limit their suppressive potential. In contrast, incompletely skewed T cell populations that produced high levels of both Th1 and Th2 cytokines were consistently only weakly encephalitogenic. Therefore, disease inhibition by Th2 cytokines may best be accomplished by intervention at earlier points preceding development of differentiated Th1 cells.

Entities:  

Mesh:

Year:  1995        PMID: 7594508

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells.

Authors:  E M Shevach; J T Chang; B M Segal
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

3.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; C Benou; A D Salama; M J Grusby; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

4.  Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis.

Authors:  C Ekerfelt; C Dahle; R Weissert; M Kvarnström; T Olsson; J Ernerudh
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

Review 5.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

6.  Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Authors:  Anna E Kersh; Lindsay J Edwards; Brian D Evavold
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

7.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 8.  Anti-cytokine vaccines and the immunotherapy of autoimmune diseases.

Authors:  David C Wraith
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

Review 9.  Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders.

Authors:  G A W Rook; V Adams; J Hunt; R Palmer; R Martinelli; L Rosa Brunet
Journal:  Springer Semin Immunopathol       Date:  2003-10-08

Review 10.  Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.

Authors:  Michael K Racke; Anne R Gocke; Mark Muir; Asim Diab; Paul D Drew; Amy E Lovett-Racke
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.